HER2-targeting Peptide Drug Conjugate with Better Penetrability for Effective Breast Cancer Therapy

Antibody-drug conjugates (ADCs) have the following advantages: target specificity; wide therapeutic index; and prolonged circulation half-life. A key limitation of ADCs, however, is the large size (~150 kDa), which markedly slows diffusion through the interstitium of solid tumors and prevents effici...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Yixia Liang, Rong Lei, Jiabao Tan, Junyue Fang, Lin Yu, Shiyu Tan, Yan Nie, Qiongchao Jiang, Xiaoyun Xiao, Phei Er Saw
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Compuscript Ltd 2023-12-01
Σειρά:	BIO Integration
Θέματα:	breast cancer cancer therapeutics enhanced tumor penetration her2 peptide-drug conjugate
Διαθέσιμο Online:	https://www.ingentaconnect.com/contentone/cscript/bioi/2023/00000004/00000004/art00004
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!